2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172200
    PD-L1/HDAC6-IN-1 2834094-36-7 98%
    PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of PD-L1 and HDAC6, with IC50 values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma.
    PD-L1/HDAC6-IN-1
  • HY-172201
    NF-κB-IN-19 98%
    NF-κB-IN-19 (Compound 8) is an NF-κB inhibitor. NF-κB-IN-19 effectively induces DNA damage, promotes the generation of ROS, and induces autophagy and apoptosis through the NF-κB signaling pathway in tumor cells. In addition, NF-κB-IN-19 can inhibit the levels of VEGF and HIF-1α, and exert antiproliferative activity in tumor cells through the PI3K/AKT and STAT-3 pathways. NF-κB-IN-19 can effectively overcome cisplatin resistance and has anti-tumor activity.
    NF-κB-IN-19
  • HY-172203
    BI-1915 752237-67-5 98%
    BI-1915, a chemical probe, is the selective inhibitor for Cathepsin S with an IC50 of 17 nM. BI-1915 can be used in research of autoimmune diseases.
    BI-1915
  • HY-172219
    CUR-IPA 98%
    CUR-IPA is a cholinesterase inhibitor, with IC50 of 5.99, 59.30, and 60.66 μM for eAChE (electric eel), hAChE (human), and hBChE (human), respectively. CUR-IPA can scavenge free radicals and has antioxidant activity. CUR-IPA can be used in the research of cognitive dysfunction.
    CUR-IPA
  • HY-172226
    P2Y14R antagonist 3 98%
    P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases.
    P2Y14R antagonist 3
  • HY-172239
    Tarvicopan 2378381-06-5 98%
    Tarvicopan is an inhibitor for complement factor D.
    Tarvicopan
  • HY-172242
    Verducatib 1887236-33-0 98.94%
    Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential.
    Verducatib
  • HY-172275
    DSPE-PEG1000-Cys-SRNLIDC (Disulfide bridge: Cys1-Cys8) 98%
    DSPE-PEG1000-pPB is a PEG compound which composed of DSPE and a cyclic oligopeptide (pPB). pPB has a strong binding affinity with PDGFRβ, which is overexpressed on activated hepatic stellate cells (HSC). DSPE-PEG1000-pPB can be used for drug delivery.
    DSPE-PEG1000-Cys-SRNLIDC (Disulfide bridge: Cys1-Cys8)
  • HY-172330
    Q1-SM-102 iodide 3079716-72-3 98%
    Q1-SM-102 iodide is a quaternary ammonium lipid derivative of SM-102 (HY-13454). Q1-SM-102 iodide can be used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA in vivo. Q1-SM-102 iodide is a carriers for targeting delivery of mRNA to immune organs.
    Q1-SM-102 iodide
  • HY-172332
    H1L1A1B3 3097638-09-7 98%
    H1L1A1B3 is an ionizable cationic lipid used in the formation of lipid nanoparticles (LNPs) for the delivery of circular RNA (circRNA). H1L1A1B3-LNPs demonstrates a fourfold increase in circRNA transfection efficiency in lung cancer cells over ALC-0315 (HY-138170). H1L1A1B3 can activate the NF-κB/IRF immune pathways.
    H1L1A1B3
  • HY-172336
    4-O10b1 98%
    4-O10b1 is an ionizable cationic lipid. 4-O10b1 can be used to prepare lipid nanoparticles (LNPs) for the delivery of mRNA in vitro and in vivo.
    4-O10b1
  • HY-172365
    P7–2302 98%
    P7-2302 inhibits PDE7 and PDE4B with IC50 of 0.18 nM and 77.3 nM. P7-2302 inhibits the efflux of P-gp and BCRP (breast cancer resistance protein), exhibits low uptake in rats brain. P7-2302 can be used as a PET tracer when labeled with 18F.
    P7–2302
  • HY-172368
    PROTAC CARM1/IKZF3 degrader-1 98%
    PROTAC CARM1/IKZF3 degrader-1 (Compound 074) inhibits CARM1, reduces the methylation level of its substrate BAF155. PROTAC CARM1/IKZF3 degrader-1 is the PROTAC degrader for IKZF 1/3 through a CRBN-dependent pathway. PROTAC CARM1/IKZF3 degrader-1 inhibits the expression of MYC protein, thereby inhibiting the proliferation of a variety of multiple myeloma cells. PROTAC CARM1/IKZF3 degrader-1 induces apoptosis in cell H929. PROTAC CARM1/IKZF3 degrader-1 overcomes immunomodulatory drugs (IMiD, such as pomalidomide) resistance. PROTAC CARM1/IKZF3 degrader-1 can be used in cancer and immunology research. (Pink: ligand for target protein CARM1/IKZF3 ligand 1 (HY-172369); Active form of target protein ligand: EZM 2302 (HY-111109); Black: linker (HY-21999); Blue: ligand for E3 ligase Cereblon Thalidomide 4-fluoride (HY-41547))
    PROTAC CARM1/IKZF3 degrader-1
  • HY-172372
    IRAK4-IN-30 2967595-45-3 98%
    IRAK4-IN-30 (Compound I) is the inhibitor for IRAK4 with IC50 of 0.6 nM.
    IRAK4-IN-30
  • HY-172374
    KV1.3-IN-2 2640023-16-9 98%
    KV1.3-IN-2 is a kv1.3 potassium channel inhibitor without affecting hERG channel activity. KV1.3-IN-2 can be used in research of immune-related diseases such as psoriasis, rheumatoid arthritis, and systemic lupus erythematosus.
    KV1.3-IN-2
  • HY-172406
    MAPK-IN-4 98%
    MAPK-IN-4 (Compound c1) is an orally active anti-inflammatory agent. MAPK-IN-4 can inhibit the expression and release of pro-inflammatory cytokines IL-6 and TNF-α induced by LPS (HY-D1056). MAPK-IN-4 can bind to IRAK4 and exert its anti-inflammatory effect by inhibiting the MAPK pathway.
    MAPK-IN-4
  • HY-172409
    CB1R antagonist 2 98%
    CB1R antagonist 2 (Compound 11g) is the antagonist for cannabinoid receptor 1 (CB1R), that inhibits MAPK/NF-κB signaling pathway and exhibits anti-inflammatory activity. CB1R antagonist 2 inhibits LPS (HY-D1056)-induced IL-6, IL-1β and TNF-α expressions in RAW264.7. CB1R antagonist 2 ameliorates OVA-induced allergic rhinitis in mouse models.
    CB1R antagonist 2
  • HY-172432
    Plodicitinib 2360992-48-7 98%
    Plodicitinib is a Janus tyrosine kinase 3/TEC family kinase inhibitor with anti-inflammatory activity.
    Plodicitinib
  • HY-172438
    Setomagpran 2991434-57-0 98%
    Setomagpran is the antagonist for mas-related G protein-coupled receptor (MRGPR), and exhibits anti-inflammatory activity.
    Setomagpran
  • HY-172535
    Lipid OA2 dihydrochloride
    Lipid OA2 dihydrochloride is an ionizable cationic lipid that can be used to prepare single-component lipid nanoparticles for siRNA delivery. Lipid OA2 dihydrochloride can effectively deliver SOCS1-siRNA to dendritic cells, silence the SOCS1 gene, and enhance their antigen-presenting ability and pro-inflammatory factor secretion capacity.
    Lipid OA2 dihydrochloride
Cat. No. Product Name / Synonyms Application Reactivity